Author

Meiby Rodríguez-González

Observed names: Meiby Rodriguez-González, Meiby de la Caridad Rodríguez González, Meiby de la Caridad Rodríguez-González, Rodríguez-González, Meiby

Institution: Finlay Institute

Observed institution: Finlay Institute

ORCID: 0000-0002-4205-0415

Observed ORCID: 0000-0002-4205-0415

OpenAlex ID: A5018304094

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial

2022 · María Eugenia Toledo-Romaní, Mayra García-Carmenate, et al. · The Lancet Regional Health - Americas · 74

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

2022 · María Eugenia-Toledo-Romaní, Leslyhana Verdecia-Sánchez, et al. · Vaccine · 38

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity

2022 · Sonia Pérez-Rodríguez, Meiby de la Caridad Rodríguez-González, et al. · Vaccine · 37

Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children

2022 · Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, et al. · International Journal of Infectious Diseases · 33

Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2–11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study

2024 · María Eugenia Toledo-Romaní, Carmen Valenzuela-Silva, et al. · The Lancet Regional Health - Americas · 12

Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children

2023 · Rocmira Perez-Nicado, Chiara Massa, et al. · Vaccines · 9

Safety and durability of the immune response after vaccination with the heterologous schedule of anti-COVID-19 vaccines SOBERANA®02 and SOBERANA® Plus in children 3–18 years old

2024 · Dagmar García-Rivera, Rinaldo Puga-Gómez, et al. · Vaccine X · 2

Safety and Cross-Neutralizing Immunity Against SARS-CoV-2 Omicron Sub-Variant After a Booster Dose with SOBERANA® Plus in Children and Adolescents

2025 · Dagmar García-Rivera, Meiby Rodríguez-González, et al. · Vaccines · 1

Seguridad, inmunogenicidad y eficacia de las vacunas SOBERANA ® 02 y SOBERANA® Plus en población pediátrica

2025 · Puga-Gómez, Rinaldo, Fonseca Hernández, Mercedes, et al. · Anales de la Academia de Ciencias de Cuba

Safety and Immunogenicity of Anti-SARS-CoV-2 Conjugate Vaccine SOBERANA 02: Phase IIb Clinical Trial

2022 · Maria Eugenia-Toledo-Romani, Mayra García Carmenate, et al. · SSRN Electronic Journal

Approach to the state of the art of data monitoring committees in clinical trials

2021 · Sonia Pérez Rodríguez, Héctor Lázaro Lara Fernández, et al. · DOAJ (DOAJ: Directory of Open Access Journals)

Works count: 11

Citation count: 206

H-index: 6

I10-index: 5